Circulating microRNA‑101 as a potential biomarker for hepatitis B virus‑related hepatocellular carcinoma

Fu,Yu; Wei,Xufu; Tang,Chengyong; Li,Jianping; Liu,Rui; Shen,Ai; Wu,Zhongjun

doi:10.3892/ol.2013.1638

Circulating microRNA‑101 as a potential biomarker for hepatitis B virus‑related hepatocellular carcinoma

Authors:
- Yu Fu
- Xufu Wei
- Chengyong Tang
- Jianping Li
- Rui Liu
- Ai Shen
- Zhongjun Wu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China, Department of Clinical Pharmacology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China, Department of Histology and Embryology, Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
Published online on: October 21, 2013 https://doi.org/10.3892/ol.2013.1638
Pages: 1811-1815

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating microRNAs (miRNAs) are emerging as promising biomarkers for cancer; however, the significance of circulating miRNAs in hepatitis B virus (HBV)‑related hepatocellular carcinoma (HCC) remains largely unknown. Based on our prior observations that miRNA‑101 (miR‑101) is downregulated by HBV and induces epigenetic modification, we sought to test whether circulating miR‑101 may serve as a potential biomarker for HCC. The expression of miR‑101 in HCCs and serum was evaluated by real‑time polymerase chain reaction. Tissue and serum miR‑101 levels were assessed in samples from patients with HBV‑related HCC and healthy controls. A potential correlation was also evaluated between miR‑101 expression and the clinicopathological features and prognosis of HCC patients. miR‑101 was downregulated in HBV‑related HCC tissues compared with adjacent noncancerous tissues. Furthermore, the miR‑101 levels in these tissues from HCC patients were significantly lower than those in tissues from control subjects. Notably, serum miR‑101 levels were found to have an inverse correlation with tissue miR‑101 expression levels. The expression of serum miR‑101 in patients with HBV‑related HCC was significantly higher than that in the healthy controls, and this increase correlated with hepatitis B surface antigen positivity, HBV DNA levels and tumor size. These results indicate that different factors govern the levels of miR‑101 in the tissue and serum of HCC patients. Given the marked and consistent increase in serum miR‑101 levels in HCC patients, circulating miR‑101 may serve as a promising biochemical marker for monitoring the progression of tumor development in HBV‑related HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Arbuthnot P and Kew M: Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol. 82:77–100. 2001. View Article : Google Scholar : PubMed/NCBI
3	Oka H, Tamori A, Kuroki T, Kobayashi K and Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 19:61–66. 1994. View Article : Google Scholar : PubMed/NCBI
4	Marrero JA and Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology. 127:S113–S119. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
8	Stefani G and Slack FJ: Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 9:219–230. 2008. View Article : Google Scholar : PubMed/NCBI
9	Mott JL: MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology. 50:630–637. 2009. View Article : Google Scholar : PubMed/NCBI
10	Visone R, Petrocca F and Croce CM: Micro-RNAs in gastrointestinal and liver disease. Gastroenterology. 135:1866–1869. 2008. View Article : Google Scholar : PubMed/NCBI
11	Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al: Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
12	Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al: miR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 27:5651–5661. 2008. View Article : Google Scholar : PubMed/NCBI
13	Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al: MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 12:2189–2204. 2008. View Article : Google Scholar : PubMed/NCBI
14	Cortez MA and Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 9:703–711. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zhu W, Qin W, Atasoy U and Sauter ER: Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2:892009. View Article : Google Scholar : PubMed/NCBI
17	Pain SJ, Barber RW, Ballinger JR, Solanki CK, Mortimer PS, Purushotham AD and Peters AM: Local vascular access of radioprotein injected subcutaneously in healthy subjects and patients with breast cancer-related lymphedema. J Nucl Med. 45:789–796. 2004.
18	Croci S, Pedrazzi G, Passeri G, Delsignore R and Ortalli I: Red cell Hb oxidation of healthy subjects compared to breast cancer patients. Anticancer Res. 22:2903–2906. 2002.PubMed/NCBI
19	Würz H, Lüben G and Bohn H: Serum levels of placental protein 10 (PP10) in women with breast cancer and genital carcinoma and in healthy male and female subjects. Arch Gynecol. 233:267–274. 1983.PubMed/NCBI
20	Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X and Wu Z: miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal. 25:439–446. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, et al: Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 14:470–477. 2008. View Article : Google Scholar : PubMed/NCBI
22	Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al: The microRNA spectrum in 12 body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
23	Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 58:1375–1381. 2009. View Article : Google Scholar : PubMed/NCBI
24	Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y and Iwai N: Plasma miR-208 as a biomarker of myocardial injury. Clin Chem. 55:1944–1949. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al: Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 106:4402–4407. 2009. View Article : Google Scholar : PubMed/NCBI
26	Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’olio V, Bernard L, et al: A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 3:495–503. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, et al: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
28	Liu S, Guo W, Shi J, Li N, Yu X, Xue J, et al: MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 56:389–396. 2012. View Article : Google Scholar : PubMed/NCBI
29	Qi P, Cheng SQ, Wang H, Li N, Chen YF and Gao CF: Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 6:e284862011. View Article : Google Scholar : PubMed/NCBI
30	Brase JC, Wuttig D, Kuner R and Sültmann H: Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 9:306 View Article : Google Scholar : 2010. View Article : Google Scholar : PubMed/NCBI
31	Wittmann J and Jäck HM: Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta. 1806:200–207. 2010.PubMed/NCBI
32	Jackson DB: Serum-based microRNAs: are we blinded by potential? Proc Natl Acad Sci USA. 106:E52009. View Article : Google Scholar : PubMed/NCBI
33	Qu KZ, Zhang K, Li H, Afdhal NH and Albitar M: Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 45:355–360. 2011. View Article : Google Scholar : PubMed/NCBI
34	Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar : PubMed/NCBI
35	Cortez MA and Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 9:703–711. 2009. View Article : Google Scholar : PubMed/NCBI
36	Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, et al: Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA. 107:6328–6333. 2010. View Article : Google Scholar : PubMed/NCBI